Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification.

Kleeman SO, Koelzer VH, Jones HJ, Vazquez EG, Davis H, East JE, Arnold R, Koppens MA, Blake A, Domingo E, Cunningham C, Beggs AD, Pestinger V, Loughrey MB, Wang LM, Lannagan TR, Woods SL, Worthley D, Consortium SC, Tomlinson I, Dunne PD, Maughan T, Leedham SJ.

Gut. 2019 Sep 28. pii: gutjnl-2019-319126. doi: 10.1136/gutjnl-2019-319126. [Epub ahead of print]

2.

Utility of surgeon-performed pre-operative ultrasound in the localisation of parathyroid adenomas.

Thomas PR, Beggs AD, Han TS.

JRSM Cardiovasc Dis. 2019 Jun 19;8:2048004019856950. doi: 10.1177/2048004019856949. eCollection 2019 Jan-Dec.

3.

Mechanisms of immunogenicity in colorectal cancer.

Sillo TO, Beggs AD, Morton DG, Middleton G.

Br J Surg. 2019 Sep;106(10):1283-1297. doi: 10.1002/bjs.11204. Epub 2019 Jun 19. Review.

4.

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer.

Brooks JM, Menezes AN, Ibrahim M, Archer L, Lal N, Bagnall CJ, von Zeidler SV, Valentine HR, Spruce RJ, Batis N, Bryant JL, Hartley M, Kaul B, Ryan GB, Bao R, Khattri A, Lee SP, Ogbureke KUE, Middleton G, Tennant DA, Beggs AD, Deeks J, West CML, Cazier JB, Willcox BE, Seiwert TY, Mehanna H.

Clin Cancer Res. 2019 Sep 1;25(17):5315-5328. doi: 10.1158/1078-0432.CCR-18-3314. Epub 2019 Jun 10.

PMID:
31182433
5.

Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.

Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, Silcock L, Whalley CM, Stockton JD, Beggs AD, Griffiths M, Abbotts B, Ijakipour H, Latheef FN, Robinson RA, White AJ, James ND, Zeegers MP, Cheng KK, Bryan RT.

BJU Int. 2019 Sep;124(3):532-544. doi: 10.1111/bju.14808. Epub 2019 Jun 19.

6.

MicroRNA changes in maternal serum from pregnancies complicated by twin-twin transfusion syndrome: A discovery study.

Mackie FL, Baker BC, Beggs AD, Stodolna A, Morris RK, Kilby MD.

Prenat Diagn. 2019 Jul;39(8):616-634. doi: 10.1002/pd.5475. Epub 2019 Jun 18.

7.

The Safety and Tolerability of a Potential Alginate-Based Iron Chelator; Results of A Healthy Participant Study.

Horniblow RD, Mistry P, Quraishi MN, Beggs AD, Van de Wiele T, Iqbal TH, Tselepis C.

Nutrients. 2019 Mar 21;11(3). pii: E674. doi: 10.3390/nu11030674.

8.

Validation of epigenetic markers to identify colitis associated cancer: Results of module 1 of the ENDCAP-C study.

Beggs AD, Mehta S, Deeks JJ, James JD, Caldwell GM, Dilworth MP, Stockton JD, Blakeway D, Pestinger V, Vince A, Taniere P, Iqbal T, Magill L, Matthews G, Morton DG; ENDCAP-C Module 1 Collaborative.

EBioMedicine. 2019 Jan;39:265-271. doi: 10.1016/j.ebiom.2018.11.034. Epub 2018 Nov 22.

9.

Disruption of CTCF-YY1-dependent looping of the human papillomavirus genome activates differentiation-induced viral oncogene transcription.

Pentland I, Campos-León K, Cotic M, Davies KJ, Wood CD, Groves IJ, Burley M, Coleman N, Stockton JD, Noyvert B, Beggs AD, West MJ, Roberts S, Parish JL.

PLoS Biol. 2018 Oct 25;16(10):e2005752. doi: 10.1371/journal.pbio.2005752. eCollection 2018 Oct.

10.

A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma.

Nieto T, Tomlinson CL, Dretzke J, Bayliss S, Price MJ, Dilworth M, Beggs AD, Tucker O.

BMJ Open. 2018 Jun 30;8(6):e020427. doi: 10.1136/bmjopen-2017-020427.

11.

Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia.

Beggs AD, James J, Caldwell G, Prout T, Dilworth MP, Taniere P, Iqbal T, Morton DG, Matthews G.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1503-1509. doi: 10.1093/ibd/izy119.

12.

Nanopore sequencing and assembly of a human genome with ultra-long reads.

Jain M, Koren S, Miga KH, Quick J, Rand AC, Sasani TA, Tyson JR, Beggs AD, Dilthey AT, Fiddes IT, Malla S, Marriott H, Nieto T, O'Grady J, Olsen HE, Pedersen BS, Rhie A, Richardson H, Quinlan AR, Snutch TP, Tee L, Paten B, Phillippy AM, Simpson JT, Loman NJ, Loose M.

Nat Biotechnol. 2018 Apr;36(4):338-345. doi: 10.1038/nbt.4060. Epub 2018 Jan 29.

13.

Whole Genome Methylation Analysis of Nondysplastic Barrett Esophagus that Progresses to Invasive Cancer.

Dilworth MP, Nieto T, Stockton JD, Whalley CM, Tee L, James JD, Noble F, Underwood TJ, Hallissey MT, Hejmadi R, Trudgill N, Tucker O, Beggs AD.

Ann Surg. 2019 Mar;269(3):479-485. doi: 10.1097/SLA.0000000000002658.

14.

Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution.

Baker AM, Huang W, Wang XM, Jansen M, Ma XJ, Kim J, Anderson CM, Wu X, Pan L, Su N, Luo Y, Domingo E, Heide T, Sottoriva A, Lewis A, Beggs AD, Wright NA, Rodriguez-Justo M, Park E, Tomlinson I, Graham TA.

Nat Commun. 2017 Dec 8;8(1):1998. doi: 10.1038/s41467-017-02295-5.

15.

KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.

Lal N, White BS, Goussous G, Pickles O, Mason MJ, Beggs AD, Taniere P, Willcox BE, Guinney J, Middleton GW.

Clin Cancer Res. 2018 Jan 1;24(1):224-233. doi: 10.1158/1078-0432.CCR-17-1090. Epub 2017 Oct 23.

16.

Mutation Frequencies in Patients With Early-Onset Colorectal Cancer.

Beggs AD.

JAMA Oncol. 2017 Nov 1;3(11):1585. doi: 10.1001/jamaoncol.2016.7089. No abstract available.

PMID:
28687834
17.

Epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.

Nieto T, Tomlinson CL, Dretzke J, Bayliss S, Dilworth M, Beggs AD, Tucker O.

BMJ Open. 2016 Dec 7;6(12):e013361. doi: 10.1136/bmjopen-2016-013361.

18.

Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.

Ward DG, Baxter L, Gordon NS, Ott S, Savage RS, Beggs AD, James JD, Lickiss J, Green S, Wallis Y, Wei W, James ND, Zeegers MP, Cheng KK, Mathews GM, Patel P, Griffiths M, Bryan RT.

PLoS One. 2016 Feb 22;11(2):e0149756. doi: 10.1371/journal.pone.0149756. eCollection 2016.

19.

Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer.

Beggs AD, Dilworth MP, Domingo E, Midgley R, Kerr D, Tomlinson IP, Middleton GW.

Oncoscience. 2015 Mar 23;2(5):508-16. eCollection 2015.

20.

An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy.

Lal N, Beggs AD, Willcox BE, Middleton GW.

Oncoimmunology. 2015 Apr 2;4(3):e976052. eCollection 2015 Mar.

21.

Surgery in the era of the 'omics revolution.

Beggs AD, Dilworth MP.

Br J Surg. 2015 Jan;102(2):e29-40. doi: 10.1002/bjs.9722. Review.

22.

Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance.

Ganapathi SK, Beggs AD, Hodgson SV, Kumar D.

Br J Cancer. 2014 Oct 14;111(8):1581-9. doi: 10.1038/bjc.2014.477. Epub 2014 Sep 16.

23.

Outcome of repair of obstetric anal sphincter injuries after three years.

Reid AJ, Beggs AD, Sultan AH, Roos AM, Thakar R.

Int J Gynaecol Obstet. 2014 Oct;127(1):47-50. doi: 10.1016/j.ijgo.2014.04.013. Epub 2014 Jun 12.

24.

Can the risk of obstetric anal sphincter injuries (OASIs) be predicted using a risk-scoring system?

McPherson KC, Beggs AD, Sultan AH, Thakar R.

BMC Res Notes. 2014 Jul 24;7:471. doi: 10.1186/1756-0500-7-471.

25.

A systematic review of transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding.

Beggs AD, Dilworth MP, Powell SL, Atherton H, Griffiths EA.

Clin Exp Gastroenterol. 2014 Apr 16;7:93-104. doi: 10.2147/CEG.S56725. eCollection 2014.

26.

A pain in the bottom.

Iqbal F, Beggs AD, Holt T, Bowley DM.

BMJ. 2013 Jul 1;347:f4192. doi: 10.1136/bmj.f4192. No abstract available.

PMID:
23818561
27.

Loss of expression and promoter methylation of SLIT2 are associated with sessile serrated adenoma formation.

Beggs AD, Jones A, Shepherd N, Arnaout A, Finlayson C, Abulafi AM, Morton DG, Matthews GM, Hodgson SV, Tomlinson IP.

PLoS Genet. 2013 May;9(5):e1003488. doi: 10.1371/journal.pgen.1003488. Epub 2013 May 9.

28.

Loss of mismatch repair protein expression in breast carcinoma in patients with Lynch Syndrome: report of two cases.

Beggs AD, Kousparos G, Hodgson SV.

Breast J. 2013 Mar-Apr;19(2):193-5. doi: 10.1111/tbj.12077. Epub 2013 Jan 7.

PMID:
23294250
29.

A study of genomic instability in early preneoplastic colonic lesions.

Beggs AD, Domingo E, Abulafi M, Hodgson SV, Tomlinson IP.

Oncogene. 2013 Nov 14;32(46):5333-7. doi: 10.1038/onc.2012.584. Epub 2012 Dec 17.

30.

Point of use ultrasound by general surgeons: review of the literature and suggestions for future practice.

Beggs AD, Thomas PR.

Int J Surg. 2013;11(1):12-7. doi: 10.1016/j.ijsu.2012.11.014. Epub 2012 Nov 30. Review.

31.

Appendicular sarcoidosis mimicking acute appendicitis.

Hunjan T, Chaudery M, Zaidi A, Beggs AD.

BMJ Case Rep. 2012 Nov 15;2012. pii: bcr2012006825. doi: 10.1136/bcr-2012-006825.

32.

Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.

Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M, Abulafi M, Hodgson SV, Fadhil W, Ilyas M, Tomlinson IP.

Oncotarget. 2012 Nov;3(11):1348-55.

33.

Whole-genome methylation analysis of benign and malignant colorectal tumours.

Beggs AD, Jones A, El-Bahrawy M, Abulafi M, Hodgson SV, Tomlinson IP.

J Pathol. 2013 Apr;229(5):697-704. doi: 10.1002/path.4132. Epub 2013 Jan 24. Erratum in: J Pathol. 2013 Dec;231(4):543. El-Bahwary, Mona [corrected to El-Bahrawy, Mona].

34.

An unusual polyp at colonoscopy.

Beggs AD, Coppen MJ, Abulafi AM.

BMJ Case Rep. 2012 Sep 17;2012. pii: bcr2012006886. doi: 10.1136/bcr-2012-006886. No abstract available.

35.

TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres.

Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, Tenesa A, Walker M, Howarth K, Ballereau S, Hodgson SV, Zauber A, Bertagnolli M, Midgley R, Campbell H, Kerr D, Dunlop MG, Tomlinson IP.

Gut. 2012 Feb;61(2):248-54. doi: 10.1136/gut.2011.239772. Epub 2011 Jun 27.

36.

Straight to colonoscopy: the ideal patient pathway for the 2-week suspected cancer referrals?

Beggs AD, Bhate RD, Irukulla S, Achiek M, Abulafi AM.

Ann R Coll Surg Engl. 2011 Mar;93(2):114-9. doi: 10.1308/003588411X12851639107917. Epub 2010 Nov 12.

37.

Peutz-Jeghers syndrome: a systematic review and recommendations for management.

Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV.

Gut. 2010 Jul;59(7):975-86. doi: 10.1136/gut.2009.198499.

PMID:
20581245
38.

A pilot study of ultrasound guided Durasphere injection in the treatment of faecal incontinence.

Beggs AD, Irukulla S, Sultan AH, Ness W, Abulafi AM.

Colorectal Dis. 2010 Sep;12(9):935-40. doi: 10.1111/j.1463-1318.2009.01927.x. Epub 2009 Apr 27.

PMID:
19438887
39.

Genomics and breast cancer: the different levels of inherited susceptibility.

Beggs AD, Hodgson SV.

Eur J Hum Genet. 2009 Jul;17(7):855-6. doi: 10.1038/ejhg.2008.235. Epub 2008 Dec 17. No abstract available.

40.

The genomics of colorectal cancer: state of the art.

Beggs AD, Hodgson SV.

Curr Genomics. 2008 Mar;9(1):1-10. doi: 10.2174/138920208783884865.

41.

The DCC gene and colorectal cancer: the story is more complex.

Beggs AD, Abulafi M, Hodgson SV.

Colorectal Dis. 2008 Jul;10(6):630. doi: 10.1111/j.1463-1318.2008.01474.x. Epub 2008 Feb 11. No abstract available.

PMID:
18266884
42.

Graduate medical school entry: Bad for state school applicants.

Beggs AD.

BMJ. 2007 Dec 8;335(7631):1169. No abstract available.

43.

Chest pain and fleeting neurological signs.

Beggs AD, Al-Rawi H, Parfitt A.

Lancet. 2005 Apr 23-29;365(9469):1514. No abstract available.

PMID:
15850639
44.

Localization of parathyroid adenomas using 11C-methionine positron emission tomography.

Beggs AD, Hain SF.

Nucl Med Commun. 2005 Feb;26(2):133-6.

PMID:
15657506
45.

C-11 methionine uptake in granulomatous disease.

Hain SF, Beggs AD.

Clin Nucl Med. 2004 Sep;29(9):585-6. No abstract available.

PMID:
15311134
46.

Use of co-registered 11C-methionine PET and computed tomography for the localisation of parathyroid adenomas.

Beggs AD, Hain SF.

Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1602. Epub 2003 Aug 23. No abstract available.

PMID:
14579103
47.

F-18 FDG-positron emission tomographic scanning and Wegener's granulomatosis.

Beggs AD, Hain SF.

Clin Nucl Med. 2002 Oct;27(10):705-6.

PMID:
12352111
48.

Bleomycin-induced alveolitis detected by FDG positron emission tomography.

Hain SF, Beggs AD.

Clin Nucl Med. 2002 Jul;27(7):522-3. No abstract available.

PMID:
12072783
49.

FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy.

Beggs AD, Hain SF, Curran KM, O'Doherty MJ.

Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):542-6. Epub 2002 Feb 27.

PMID:
11914894
50.

FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy.

Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN.

Eur J Nucl Med. 2001 Sep;28(9):1336-40.

PMID:
11585292

Supplemental Content

Loading ...
Support Center